MiR-29b Inhibits Ventricular Remodeling By Activating Notch Signaling Pathway in the Rat Myocardial Infarction Model
Background: To study the effect of miR-29b on myocardial infarction via Notch signaling pathway in rats.
Methods: The rat acute myocardial infarction (AMI) models were established and were divided into AMI group, sham group and normal group (N = 10 in each group). HE (Hemotoxylin and eosin) staining was used to detect whether the model was constructed successfully. MiR-29b mimics, inhibitors, mimics negative control (NC) were transfected into H9c2 (2-1) cells. Then, cells were divided into a mimics group, inhibitor group, NC group, and blank group. The relative expression levels of miR-29b, Notch1, DII4 and Hesl were detected by qRT-PCR. The expression of NICD1 was detected by Western blotting.
Results: The rat AMI model was successfully constructed. Compared with normal and sham groups, the miR-29b expression was down-regulated, while the expression of Notch1, DII4 and Hesl was increased, and the NICD1 protein expression was increased in the myocardial infarction area of the AMI group (P < .05). Compared with the NC and blank groups, the relative expression of Notch1, DII4, Hesl and NICD1 were upregulated in the mimics group (P < .05), whereas the expression of Notch1, DII4, Hesl and NICD1 in the inhibitor group was decreased (P < .05).
Conclusion: MiR-29b inhibited myocardial fibrosis and cardiac hypertrophy by activating the Notch signaling pathway and protected myocardium against myocardial infarction.
Chen L, Anjak A, Zhou M, et al. 2010. Abstract 21055: Direct Nicd1 Overexpression Enhances Cardiac Commitment of Cpcs and Improve Heart Repair After Acute Myocardial Infarction via Notch1/gata4 Signaling. Circulation 122:A21055.
Chen X, Xiao W, Chen W, et al. 2017. MicroRNA-26a and -26b inhibit lens fibrosis and cataract by negatively regulating Jagged-1/Notch signaling pathway. Cell Death & Differentiation 24:1431.
Croquelois A, Domenighetti AA, Nemir M, et al. 2008. Control of the adaptive response of the heart to stress via the Notch1 receptor pathway. Journal of Experimental Medicine 205:3173-85.
E vR, LB S, JE T, et al. 2008. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proceedings of the National Academy of Sciences of the United States of America 105:13027-32.
Fan YH, Dong H, Pan Q, et al. 2011. Notch signaling may negatively regulate neonatal rat cardiac fibroblast-myofibroblast transformation. Physiological Research 60:739-48.
Gopalakrishnan N, Sivasithamparam ND, Devaraj H. 2014. Synergistic association of Notch and NFκB signaling and role of Notch signaling in modulating epithelial to mesenchymal transition in colorectal adenocarcinoma. Biochimie 107:310-8.
Gude NA, Emmanuel G, Wu W, et al. 2008. Activation of Notch-mediated protective signaling in the myocardium. Circulation Research 102:1025-35.
Jin JL, Deng ZT, Lyu RG, et al. 2017. [Expression changes of Notch and nuclear factor-κB signaling pathways in the rat heart with myocardial infarction]. China Medical Abstracts (Internal Medicine) 45:507-12.
Lew WY, Bayna E, Dalle ME, et al. 2014. Myocardial fibrosis induced by exposure to subclinical lipopolysaccharide is associated with decreased miR-29c and enhanced NOX2 expression in mice. Plos One 9:e107556.
Li Y, Hiroi Y, Liao JK. 2010. Notch Signaling as an Important Mediator of Cardiac Repair and Regeneration After Myocardial Infarction. Trends in Cardiovascular Medicine 20:228-31.
Li Y, Hiroi Y, Ngoy S, et al. 2011. Notch1 in Bone Marrow-derived Cells Mediates Cardiac Repair Following Myocardial Infarction. Circulation 123:866.
Lin QX, Yong-Heng FU, Huang H, et al. 2012. miR-29b mediates effect of carvedilol on inhibition of acute myocardium infarction-induced myocardial fibrosis. Chinese Journal of Pathology Physiology.
Melchiorbecker A, Dai G, Ding Z, et al. 2011. Deficiency of Biglycan Causes Cardiac Fibroblasts to Differentiate into a Myofibroblast Phenotype. Journal of Biological Chemistry 286:17365-75.
Nistri S, Sassoli C, Bani D. 2017. Notch Signaling in Ischemic Damage and Fibrosis: Evidence and Clues from the Heart. Frontiers in Pharmacology 8.
Pei H, Du J, Song X, et al. 2016. Melatonin prevents adverse myocardial infarction remodeling via Notch1/Mfn2 pathway. Free Radical Biology & Medicine 97:408-17.
Qi H, Liu Y, Li S, et al. 2017. Activation of AMPK Attenuated Cardiac Fibrosis by Inhibiting CDK2 via p21/p27 and miR-29 Family Pathways in Rats. Molecular Therapy Nucleic Acids 8:277-90.
Smrčka M, Šána J, Fadrus P, et al. 2016. Global microRNA Expression Analysis of Sox-2 positive andNegative Glioblastoma Cells. 76:1959-.
Wang Z, Dong Y, Lan Y. 2016. Dose response of spironolactone improved ventricular remodeling after acute myocardial infarction. Journal of Cardiovascular & Pulmonary Diseases.
Wu F, Yu B, Zhang X, et al. 2017. Cardioprotective effect of Notch signaling on the development of myocardial infarction complicated by diabetes mellitus. Experimental & Therapeutic Medicine 14:3447.
Yanbing LI, Qiang LI, Guan X, et al. 2016. Analysis of acute myocardial infarction caused by coronary artery occlusion. Journal of Clinical Cardiology.
Yang F, Li P, Li H, et al. 2015. microRNA-29b Mediates the Antifibrotic Effect of Tanshinone IIA in Postinfarct Cardiac Remodeling. J Cardiovasc Pharmacol 65:456-64.
Zhang Y, Kanter EM, Yamada KA. 2010. Remodeling of Cardiac Fibroblasts Following Myocardial Infarction Results in Increased Gap Junction Intercellular Communication. Cardiovascular Pathology the Official Journal of the Society for Cardiovascular Pathology 19:e233.
Zhang Y, Huang X, Wei L, et al. 2014. miR-29b as a Therapeutic Agent for Angiotensin II-induced Cardiac Fibrosis by Targeting TGF-|[beta]|/Smad3 signaling. Molecular Therapy the Journal of the American Society of Gene Therapy 22:974-85.
Zhao S, Xiao X, Sun S, et al. 2018. MicroRNA-30d/JAG1 axis modulates pulmonary fibrosis through Notch signaling pathway. Pathology - Research and Practice.
Zhou X, Chen X, Cai JJ, et al. 2015. Relaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway. 9:4599-611.
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).